Corrigendum to: Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime [Journal of Infection 2008 (56) 35-39] (DOI:10.1016/j.jinf.2007.09.011);Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime

Journal of Infection

Volumn 56, Issue 1, 2008, Pages 35-39

  Mastoraki, Ekaterini ^a   Michalopoulos, Argyris ^a   Kriaras, Ioannis ^a   Mouchtouri, Ero ^a   Falagas, Matthew ^a   Karatza, Dimitra ^a   Geroulanos, Stefanos ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Antibiotic prophylaxis; CABG; Generic formulations; Original antibiotics; Postoperative infections

Indexed keywords

CEFUROXIME; GENERIC DRUG; NORMAFENAC; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATIENT SAFETY; POSTOPERATIVE INFECTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEPTIC SHOCK; SURGICAL INFECTION;

EID: 37148999023     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.02.004     Document Type: Erratum

References (16)

1. Hendeles L., Dorf A., Stecenko A., and Weinberger M. Treatment failure after substitution of generic pancrelipase capsules. JAMA 263 (1990) 2459-2461
2. Jumao-as A., Bella I., Craig B., Lowe J., and Dasheiff R.M. Comparison of steady-state blood levels of two carbamazepine formulations. Epilepsia 30 (1989) 67-70
3. Meyer M., Chan K., and Bolton S. Generic warfarin: implications for patient care-another view. Pharmacotherapy 18 (1998) 884-886
4. Wagner J.G., Welling P.G., Lee K.P., and Walker J.E. In vivo and in vitro availability of commercial warfarin tablets. J Pharm Sci 60 (1971) 666-667
5. Kriaras I., Michalopoulos A., Michalis A., Palatianos G., Economopoulos G., Anagnostopoulos C., et al. Antibiotic prophylaxis in cardiac surgery. J Cardiothor Surgery 38 (1997) 605-610
6. Kriaras I., Michalopoulos A., Turina M., and Geroulanos S. Evolution of antimicribial prophylaxis in cardiovascular surgery. Eur J Cardiothor Surg 18 (2000) 440-446
7. Oakley R., and Wright J. Postoperative mediastinitis: classification and management. Ann Thorac Surg 61 (1996) 1030-1036
8. Gaynes R.P., and Horan T.C. Surveillance of nosocomial infections. Appendix A: CDC definitions of nosocomial infections. In: Mayhall C.G. (Ed). Hospital epidemiology and infection control (1996), Williams & Wilkins, Baltimore 1-14
9. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
10. Meyer B.M. FDA position on product selection for "narrow therapeutic index" drugs. Am J Health Syst Pharm 54 (1997) 1630-1632
11. Anonymous. Generic drugs. The medical letter on drugs and therapeutics 1999;41:47-48.
12. Banahan B.F., and Kolassa E.M. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med 157 (1997) 2080-2088
13. Barone J.A., Colaizzi J.L., and Zorn B.K. The generic drug scandal and its implications for pharmacy professionals. DICP Ann Pharmacother 24 (1990) 98-99
14. Wittkowsky A.K. Generic warfarin: implications for patients care. Pharmacotherapy 17 (1997) 640-643
15. Benet L.Z., and Goyan J.E. Bioequivalence and "narrow therapeutic index" drugs. Pharmacotherapy 15 (1995) 433-440
16. Patnaik R.N., Lesko L.J., Chen M.L., and Williams R.L. Individual bioequivalence: new concepts in the statistical assessment of bioequivalence metrics. Clin Pharmacokinet 33 (1997) 1-6